ArticleJournal of general internal medicine2013
Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.
Article in Journal of general internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02295384 (Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia), which is not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- What is polypharmacy in people living with HIV/AIDS? A systematic review.AIDS research and therapy · 2022Pooled it
- A Systematic Review of Health Literacy Interventions for People Living with HIV.AIDS and behavior · 2017Pooled it
- Prevalence and Severity of Potential Drug-Drug Interactions in People Living with HIV on Antiretroviral Therapy in the United States.Infectious diseases and therapy · 2026Article
- Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Impact of a CMO-Based Pharmaceutical Care Model on 3-HIT Criteria in Older People Living with HIV: The DIS3HIT Project.Patient preference and adherence · 2026Article
- Safety and efficacy of BIC/FIC/TAF in older PLHIV: impact on bone density, renal function, and lipid profiles in a real-world Chinese cohort.BMC infectious diseases · 2025Article
- EVALUATION OF SCREENING TOOL OF OLDER PEOPLE'S PRESCRIPTIONS (STOPP) CRITERIA IN AN URBAN COHORT OF OLDER PEOPLE WITH HIV.Pharmacoepidemiology · 2025Article
- Article
- The prevalence of antiretroviral drug interactions with other drugs used in women living with HIV and its association with HIV drug change and patient compliance.BMC infectious diseases · 2024Article
- An update on drug-drug interactions in older adults living with human immunodeficiency virus (HIV).Expert review of clinical pharmacology · 2024Review
- Polypharmacy Is Associated With Slow Gait Speed and Recurrent Falls in Older People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- The Impact of Number of Medications on Falls in Aging Persons with Human Immunodeficiency Virus.Life (Basel, Switzerland) · 2023Article
- Potential drug-drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia.British journal of clinical pharmacology · 2023Article
- Potentially inappropriate medications according to Marc, STOPP and PRISCUS criteria in a cohort of elderly HIV+ patients. The COMMPI project.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Geriatric Conditions Associated with Nonadherence to Antiretroviral Therapy Among Older People with HIV: The Importance of Frailty.AIDS patient care and STDs · 2022Article
- Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan.HIV medicine · 2022Article
- Article
- Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis.Therapeutic advances in drug safety · 2022Article
- Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Epidemiology of multimorbidity among people living with HIV in sub-Saharan Africa: a systematic review protocol.BMJ open · 2020Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong aging HIV-infected adults, polypharmacy and its consequences have not been well-described.
objectiveTo characterize the extent of polypharmacy and the risk of antiretroviral (ARV) drug interactions among persons of different ages. DESIGN AND
participantsCross-sectional analysis among patients within the HIV Outpatient Study (HOPS) cohort who were prescribed ARVs during 2006-2010. MAIN MEASURES: We used the University of Liverpool HIV drug interactions database to identify ARV/non-ARV interactions with potential for clinical significance. KEY
resultsOf 3,810 patients analyzed (median age 46 years, 34 % ≥ 50 years old) at midpoint of observation, 1,494 (39 %) patients were prescribed ≥ 5 non-ARV medications: 706 (54 %) of 1,312 patients ≥ 50 years old compared with 788 (32 %) of 2,498 patients < 50 years. During the five-year period, the number of patients who were prescribed at least one ARV/non-ARV combination that was contraindicated or had moderate or high evidence of interaction was 267 (7 %) and 1,267 (33 %), respectively. Variables independently associated with having been prescribed a contraindicated ARV/non-ARV combination included older age (adjusted odds ratio [aOR] per 10 years of age 1.17, 95 % CI 1.01-1.35), anxiety (aOR 1.78, 95 % CI 1.32-2.40), dyslipidemia (aOR 1.96, 95 % CI 1.28-2.99), higher daily non-ARV medication burden (aOR 1.13, 95 % CI 1.10-1.17), and having been prescribed a protease inhibitor (aOR 2.10, 95 % CI 1.59-2.76). Compared with patients < 50 years, older patients were more likely to have been prescribed an ARV/non-ARV combination that was contraindicated (unadjusted OR 1.44, 95 % CI 1.14-1.82), or had moderate or high evidence of interaction (unadjusted OR 1.29, 95 % CI 1.15-1.44).
conclusionsA substantial percentage of patients were prescribed at least one ARV/non-ARV combination that was contraindicated or had potential for a clinically significant interaction. As HIV-infected patients age and experience multiple comorbidities, systematic reviews of current medications by providers may reduce risk of such exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.